Heart Failure Clinical Trials

Find Heart Failure Clinical Trials Near You

A Phase 1b, Multi-Center, Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Hepatic Pharmacodynamics of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Heart Failure With Preserved Ejection Fraction (HFpEF)

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Must be willing to participate in the study and provide written informed consent.

• Male and female adults ≥18 years of age.

• Suspected or confirmed diagnosis of fibrotic MASH suggested by the historical data and meets at least 1 criteria for fibrotic MASH

• Confirmed diagnosis of HFpEF

• Structural and/or functional heart disease based on echocardiographic evaluation.

• eGFR ≥45 mL/min/1.73 m2

• Female patients of reproductive potential are eligible if they have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use 1 highly effective birth control method during the study and for at least 30 days after study drug administration. Highly effective birth control methods include hormonal and non-hormonal intrauterine device, combination estrogen-progesterone hormonal contraception (oral, transdermal, or vaginal), tubal ligation, a vasectomized or sterile male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from Screening, throughout the study and for at least 30 days after study drug administration.

Locations
United States
Arizona
Arizona Clinical Trials
RECRUITING
Peoria
California
FOMAT - Clinicas Mi Salud
RECRUITING
Oxnard
Florida
Covenant Metabolic Specialist
RECRUITING
Fort Myers
Covenant Metabolic Specialist
RECRUITING
Riverview
Covenant Metabolic Specialist
RECRUITING
University Park
Contact Information
Primary
Ashley Magnavita
amagnavita@madrigalpharma.com
+1 267-806-1293
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2027-12
Participants
Target number of participants: 90
Treatments
Experimental: Arm 1 - Resmetirom
Participants will receive resmetirom orally once daily for 24 weeks. Resmetirom dose will be based on actual body weight: 80 mg once daily for participants weighing \<100 kg and 100 mg once daily for participants weighing ≥100 kg. Dose reduction by 20 mg will be implemented for concomitant use of a moderate CYP2C8 inhibitor, as specified in the protocol
Placebo_comparator: Arm 2 - Placebo Comparator
Participants will receive matching placebo orally once daily for 24 weeks.
Sponsors
Leads: Madrigal Pharmaceuticals, Inc.

This content was sourced from clinicaltrials.gov